Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
164 Results for "
Diffuse large B-cell lymphoma
" in MedChemExpress (MCE) Product Catalog:
Products (164)
164 Results for "Diffuse large B-cell lymphoma" in MCE Product Catalog:
Cat. No.: HY-173097
CAS No.: 2086298-33-9
Synonyms: VH032-Boc derivative 1
Research Areas:
(S,R,S)-AHPC-Boc derivative 1 (VH032-Boc derivative 1) is a derivative of (S,R,S)-AHPC-Boc (HY-123109), which is applicable to research related to PROTAC synthesis .
Cat. No.: HY-175002
CAS No.: 3051829-20-7
PI3Kδ-IN-24 is a selective PI3Kδ inhibitor (IC50 = 0.1 nM). PI3Kδ-IN-24 exhibits significant antiproliferative effects against PI3Kδ-overexpressing cancer cell lines. PI3Kδ-IN-24 reduces p-AKT levels and induces cell cycle arrest and apoptosis in tumor cells. PI3Kδ-IN-24 is useful in cancer research, such as diffuse large B-cell lymphoma (DLBCL) .
Cat. No.: HY-177730
Research Areas:
PROTAC BRD4 Degrader-40 is a BRD4 PROTAC degrader. PROTAC BRD4 Degrader-40 binds to Cereblon and recruits the CRL4 CRBN E3 ubiquitin ligase complex, mediates BRD4 degradation via the ubiquitin-proteasome pathway, and does not induce the degradation of classic CRBN neo-substrates IKZF1 and IKZF3. PROTAC BRD4 Degrader-40 induces BRD4 degradation in cancer cells. PROTAC BRD4 Degrader-40 can be used in research related to diffuse large B-cell lymphoma and acute myeloid leukemia .
Cat. No.: HY-W1115268
CAS No.: 3043925-99-8
Research Areas:
E3 Ligase Ligand-linker Conjugate 231 is an E3 ligase ligand-linker conjugate. E3 Ligase Ligand-linker Conjugate 231 can be used for the synthesis of the PROTAC BRD9 Degrader-8 (HY-162651) .
Cat. No.: HY-181355
CAS No.: 3093642-29-3
Target:
Research Areas:
PROTAC EZH2 Degrader-28 is an EZH2 PROTAC degrader. PROTAC EZH2 Degrader-28 promotes the ubiquitination and degradation of EZH2. PROTAC EZH2 Degrader-28 can be used for lymphoma-related research .
Cat. No.: HY-173641
CAS No.: 3067681-22-2
Research Areas:
MNN-02-155 is a bivalent molecular glue with with dual binding to p300/CBP and BCL6. MNN-02-155 induces potent activation of the BCL6-target reporter gene and cell death. MNN-02-155 can be used for the study of diffuse large B cell lymphomas (DLBCLs) .
Synonyms: BMF-219; Menin-MLL inhibitor 21
Target:
Research Areas:
Icovamenib (BMF-219) is a selective, orally active, irreversible Menin inhibitor. Icovamenib forms a stable and irreversible covalent bond with Menin. Icovamenib promotes selective and controlled proliferation of beta cells and improvement of beta cell function in ex vivo human islet cultures. Icovamenib enhances glycemic control in animal diabetic models. Icovamenib induces a dose-dependent enhancement in insulin secretion potentiated by the GLP-1 RA. Icovamenib can be used for the study of multiple hematologic malignancies, solid tumors, and diabetes mellitus, such as diffuse large B-cell lymphoma (DLBCL), multiple myeloma (MM) and chronic lymphocytic leukemia and type 2 diabetes .
Cat. No.: HY-168614
CAS No.: 2991817-99-1
Target:
Research Areas:
MGD-4 is an orally active cereblon-dependent molecular glue degrader with a phthalazinone scaffold. MGD-4 degrades the Ikaros family proteins IKZF1, IKZF2 and IKZF3 in a dose-dependent manner, with DC50 values of 67.2 nM, 918.2 nM and 95.8 nM, respectively. MGD-4 exhibits weak degradation activity against CK1α. MGD-4 inhibits the viability of multiple myeloma (MM) and acute myeloid leukemia (AML) cells and induces cell apoptosis. MGD-4 is used for the research of multiple myeloma, acute myeloid leukemia, diffuse large B-cell lymphoma and related hematological malignancies .
Cat. No.: HY-181300
CAS No.: 3093642-23-7
Target:
Research Areas:
PROTAC EZH2 Degrader-17 (compound 52) is a PROTAC protein degrader targeting EZH2 with an antiproliferative IC50 of 18.32 μM in lymphoma cells. PROTAC EZH2 Degrader-17 exhibits antiproliferative activity against lymphoma cells. PROTAC EZH2 Degrader-17 can be used for the research of lymphoma .
Cat. No.: HY-181412
CAS No.: 3093642-24-8
Target:
Research Areas:
PROTAC EZH2 Degrader-43 (compound 59) is a PROTAC protein degrader targeting EZH2 with an IC50 of 21.73 μM against SU-DHL-6 cells. PROTAC EZH2 Degrader-43 can be used for the research of lymphoma .
Cat. No.: HY-117622
CAS No.: 1388894-17-4
Target:
Research Areas:
ND-2110 is a selective IRAK4 inhibitor (Ki: 7.5 nM). ND-2110 binds to the ATP pocket of IRAK4. ND-2110 targets
the subset of activated B cell-like (ABC) subtype of diffuse large B cell lymphoma (DLBCL) cell lines with MYD88 L265P mutations,. ND-2110 inhibits LPS-induced TNF production, alleviates collagen-induced arthritis, and blocks gout formation in mouse models .
Cat. No.: HY-138834
CAS No.: 1042673-20-0
Research Areas:
JH-I-25 is an orally active IRAK1 and IRAK4 inhibitor. JH-I-25 inhibits LPS-induced IRAK4 phosphorylation, IRAK1 degradation, MAPK activation, and the expression of proinflammatory cytokines TNF-α and IL-6 in lung tissues. JH-I-25 improves the survival rate of LPS-induced septic mice and serves as an IRAK4 recruiter in the design of proteolysis-targeting chimeric molecules. JH-I-25 can be used in research related to diffuse large B-cell lymphoma, Waldenström's macroglobulinemia, septic shock, rheumatoid arthritis, atherosclerosis, Alzheimer's disease, acute lung injury, sepsis, and psoriasis .
Cat. No.: HY-168615
CAS No.: 2991818-13-2
Research Areas:
MGD-28 is an orally effective cereblon-dependent molecular glue degrader that potently degrades CK1α, IKZF1, IKZF2, and IKZF3, with respective DC50 values of 7.8, 3.8, 56.3, and 7.1 nM. MGD-28 also induces the degradation of multiple novel substrate proteins including ZFP91, DTWD1, ZNFX1, MBD1, and MBD3 via a CRBN/Cullin- and proteasome-dependent mechanism. MGD-28 induces cell apoptosis. MGD-28 is used in the research of multiple myeloma, acute myeloid leukemia, diffuse large B-cell lymphoma, and related malignancies .
Cat. No.: HY-176701
CAS No.: 3025838-18-7
Target:
Research Areas:
PRMT5-MTA-IN-4 (Compound 30) is a potent irreversible protein arginine methyltransferase 5 (PRMT5) inhibitor (IC50=8 nM). PRMT5-MTA-IN-4 blocks arginine methylation, inhibiting ribosomal RNA processing and cell cycle-related protein expression. PRMT5-MTA-IN-4 exhibits antiproliferative activity in multiple tumor cell lines (e.g., IC50=0.3 μM in DLD-1 cells). PRMT5-MTA-IN-4 is promising for research of hematological malignancies, such as acute myeloid leukemia, diffuse large B-cell lymphoma .
Cat. No.: HY-168654
CAS No.: 3090685-34-7
WEE1 degrader 1 (Compound 10) is a CRBN-dependent molecular glue degrader of WEE1 and casein kinase 1α (CK1α) with sub-2 nM DC50 values for both targets. WEE1 degrader 1 can be used for the research of acute lymphoblastic leukemia, acute monocytic leukemia, acute promyelocytic leukemia, colorectal adenocarcinoma, diffuse large b cell lymphoma .
Cat. No.: HY-100507A
CAS No.: 1398053-45-6
Synonyms: CC 122 hydrochloride
Target:
Research Areas:
Avadomide hydrochloride (CC 122 hydrochloride) is the hydrochloride form of Avadomide (HY-100507). Avadomide hydrochloride is an orally active cereblon modulator. Avadomide hydrochloride modulates cereblon E3 ligase activity, inhibits NF-κB pathway, arrests the cell cycle at G1 phase, and thus induces apoptosis in cancer cell PDAC. Avadomide hydrochloride exhibits potent antitumor and immunomodulatory activities .
Cat. No.: HY-100507R
CAS No.: 1015474-32-4
Synonyms: CC 122 (Standard)
Research Areas:
Avadomide (Standard) is the analytical standard of Avadomide. This product is intended for research and analytical applications. Avadomide is an orally active cereblon modulator. Avadomide modulates cereblon E3 ligase activity, inhibits NF-κB pathway, arrests the cell cycle at G1 phase, and thus induces apoptosis in cancer cell PDAC. Avadomide exhibits potent antitumor and immunomodulatory activities .
Cat. No.: HY-P9959
CAS No.: 635715-01-4
Synonyms: CMC-544; PF-5208773; WAY-207294
Target:
Research Areas:
Inotuzumab ozogamicin (CMC-544) is an antibody-targeted chemotherapy agent composed of a humanized anti-CD22 antibody Inotuzumab (HY-P99264) conjugated to Calicheamicin (HY-19609). Inotuzumab ozogamicin and G544 bind human CD22 with similar affinities (Kd ≈ 150 pM). Inotuzumab ozogamicin has demonstrated efficacy against CD22 + B-cell non-Hodgkin’s lymphoma. Inotuzumab ozogamicin can be used in the research of acute lymphoblastic leukemia .
Cat. No.: HY-P9959A
CAS No.: 635715-01-4
Synonyms: CMC-544 (solution); PF-5208773 (solution); WAY-207294 (solution)
Target:
Research Areas:
Inotuzumab ozogamicin solution (CMC-544 solution) is an antibody-targeted chemotherapy agent composed of a humanized anti-CD22 antibody conjugated to Calicheamicin (HY-19609). Inotuzumab ozogamicin solution and G544 bind human CD22 with similar affinities (Kd ≈ 150 pM). Inotuzumab ozogamicin solution has demonstrated efficacy against CD22 + B-cell non-Hodgkin’s lymphoma. Inotuzumab ozogamicin solution can be used in the research of acute lymphoblastic leukemia .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
